Your prediction
SELLAS Life Sciences Group Inc Stock
A loss of -2.910% shows a downward development for SELLAS Life Sciences Group Inc.
Our community identified positive and negative aspects for SELLAS Life Sciences Group Inc stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the SELLAS Life Sciences Group Inc stock. On the other hand our users think that "Innovation" could be a problem in the future.
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Pros and Cons of SELLAS Life Sciences Group Inc in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of SELLAS Life Sciences Group Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -2.910% | -12.851% | -32.973% | 520.887% | 206.173% | 479.439% | 20.556% |
| Beximco Pharmaceuticals Ltd. GDR | 0.950% | 3.922% | 17.778% | 23.832% | 18.304% | 38.021% | -39.773% |
| Eledon Pharmaceuticals Inc. | -2.760% | -10.759% | -15.060% | 10.156% | 120.313% | 141.026% | -48.257% |
| Grifols S.A. ADR | -2.110% | 7.752% | 12.097% | -24.865% | -8.553% | -23.626% | -46.182% |